Why StemCells (STEM) Stock Is Gaining Today

NEW YORK (TheStreet) -- StemCells (STEM) shares shot up 12% to $2.24 on Wednesday after analysts at Brinson Partick assumed coverage on the company's stock with an "outperform" rating and a $7 price target on the company's shares.

The stem cell therapy research company recently reported positive data from the first human neural stem cell transplantation in chronic spinal cord injury (SCI) and geographic atrophy age-related macular degeneration (GA-AMD) with its highly purified human neural HuCNS-SC stem cells.

Must ReadWarren Buffett's 25 Favorite Stocks

TheStreet Ratings team rates STEMCELLS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate STEMCELLS INC (STEM) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally high debt management risk."

If you liked this article you might like

These 5 Stocks Under $10 Could Make You a Lot of Money

StemCells (STEM) Stock Plummets, CEO, CFO Resign

One Reason Why StemCells (STEM) Stock Is Down Today

Closing Bell: Crude Oil Rallies Into Day Four; U.S. Stocks Fall From Records

StemCells (STEM) Stock Skyrockets on Microbot Medical Merger